Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,470,347

« Back to Dashboard
Patent 8,470,347 protects KALETRA and NORVIR and is included in two NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir There are ten tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,470,347

Title:Self-emulsifying active substance formulation and use of this formulation
Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
Inventor(s): Berndl; Gunther (Herxheim, DE), Breitenbach; Jorg (Mannheim, DE), Heger; Robert (Heidelberg, DE), Stadler; Michael (Neulu.beta.heim, DE), Wilke; Peter (Ludwigshafen, DE), Rosenberg; Jorg (Ellerstadt, DE)
Assignee: AbbVie Deutschland GmbH and Co KG (Wiesbaden, DE)
Application Number:10/296,451
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 283rd percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXNo8,470,347*PEDMar 17, 2027Y
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYes8,470,347*PEDMar 17, 2027Y
TABLET;ORAL022417-001Feb 10, 2010RXYes8,470,347*PEDMar 17, 2027Y
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,470,347

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 26 698May 30, 2000
PCT Information
PCT FiledMay 29, 2001PCT Application Number:PCT/EP01/06116
PCT Publication Date:December 06, 2001PCT Publication Number: WO01/91727

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.